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Background: Numerous studies examining the relationship between CD44 expression and prognostic impact in
patients with osteosarcoma have yielded inconclusive results. The aim of this meta-analysis was carried out to
investigate the relationship between CD44 expression and the survival in patients with osteosarcoma.
Methods: We therefore conducted a meta-analysis to provide a comprehensive evaluation of the prognostic role of
CD44 expression on the overall survival rate and metastasis, which compared the positive and negative expression
of CD44 in patients of the available studies.
Results: A detailed search was made in MEDLINE and EMBASE for relevant original articles published in English.
Finally, a total of six studies with 329 osteosarcoma patients were involved to estimate the relationship between
CD44 expression and metastasis of tumor and overall survival. Positive expressions of CD44 did not predict
neoplasm metastasis (RR = 1.36, 95% CI: 1.00–1.84, P = 0.50), and the results indicated that higher expression of
CD44 could not predict poorer survival in osteosarcoma with the pooled HR of 0.55 (95% CI: 0.27–1.13, P = 0.47).
Conclusions: The findings from this present meta-analysis suggest that CD44 expression is not associated with
overall survival rate and metastasis in osteosarcoma.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1373995521295618
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Osteosarcoma is the most common malignant primary
bone tumor and the majority of these tumors occur among
children and adolescents [1-3]. Despite the development
of neoadjuvant chemotherapy, the 5-year survival rate for
patients with high-grade osteosarcoma is still less than
50% [4]. The prognostic factors that have been implicated
include demographics (age and sex), tumor size, site, stage,
and response to chemotherapy. However, the mechanism
of prognosis in osteosarcoma patients is still not fully
understood. Therefore, a better understanding into its
basic biology is urgently needed to identify its prognostic
markers and therapeutic targets [5,6]. In recent years, the* Correspondence: yxphpwk@163.com
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unless otherwise stated.expression of certain biological molecules has been identi-
fied as potential prognostic markers for osteosarcoma,
including the expression of CD44.
CD44 is the major hyaluronan (HA) receptor [7], and
CD44 bound to HA has been proven to participate in
various tumor biological activities, including tumor
progression, metastasis and proliferation [8,9]. Some
variant isoforms of CD44 (CD44V) are reportedly asso-
ciated with increased invasion, metastasis, and poor
prognosis [10]. It has been reported that CD44V6 can
regulate the extracellular matrix, promote cell motility,
and suppress tumor apoptosis. In fact, CD44V6 has been
implicated in promoting tumor progression [11]. CD44
proteins have been studied in relation to tumor malig-
nancy and metastatic potential. The prognostic value of
CD44 for patients with cancer has been reported in vari-
ous solid tumors, including colon, lung, and breast cancer
[12-14]. With respect to osteosarcoma, the relationshipThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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versial [15,16].
Most of earlier studies suggested CD44 high expression
was associated with high risk of tumor metastasis and
worse survival in patients with osteosarcoma. However,
some other studies showed insignificant or opposite
results. Therefore, the aim of this meta-analysis was
carried out to investigate the relationship between CD44
expression and the survival in patients with osteosarcoma.
We also discuss the possibility of using CD44 as a prog-
nostic marker in osteosarcoma.
Methods
Search strategy
The PubMed, EMBASE, and MEDLINE databases were
searched, in addition to the Cochrane Central Register of
Controlled Trials, to locate articles (published between
January 1994 and January 2014), including articles refer-
enced in the publications. The search strategy included
the following keywords variably combined by “CD44”,
“osteosarcoma”, “bone tumor” and “prognosis”. Internet
search engines were also used to perform a manual
search for abstracts from international meetings, which
were then downloaded and studied.
Inclusion and exclusion criteria
Studies met the inclusion criteria if they studied the
patients with osteosarcoma, measured the expression of
CD44 in cancer tissue and investigated the association
betweenCD44 expression levels and survival out come.
When a study reporting the same patient cohort was
included in several publications, only the most recent
or complete study was selected. Studies of case reports,
letters, and reviews without original data; non-English
papers; animal or laboratory studies; and studies of
nondichotomousCD44 expression levels and absence
of survival outcome were excluded. If any doubt of
suitability remained after the abstract was examined,
the full manuscript was obtained [17].
Data extraction
Two review authors assessed the methodological quality
of potentially eligible studies, without consideration of the
results. Extracted data were then crosschecked between
the two authors to rule out any discrepancy. Data regard-
ing the following for each included studies were extracted
independently: first authors’ surname, publication year,
origin country, sample size, CD44 assessment methods
and the cut-off definition, and HR of CD44 expression for
overall survival (OS) as well as corresponding 95% confi-
dential interval (CI) and P value. Multivariate Cox hazard
regression analysis reported in the article was included in
the present analysis. Disagreements were discussed by the
authors and resolved by consensus.Statistical analysis
The statistical analysis was carried out using the Review
Manager (RevMan) software version 5.0(The Nordic
Cochrane Centre, The Cochrane Collaboration, Copenhagen,
Denmark).All these HRs and 95% confidence interval(CI)
were calculated following Tierney’s method. Pooled HR
was calculated using a fixed-effects model or random-
effects model to evaluate the relationship between
CD44expression and overall survival. I2 statisticswas used
to evaluate the between-study heterogeneity analysis in
this meta-analysis [18]. The random effects model was
used when an obvious heterogeneity was observed among
the included studies (I2 > 50%). The fixed effects model
was used when there was no significant heterogeneity
between the included studies (I2 ≤ 50%). Publication bias
was estimated using a funnel plot with an Egger’s line
arregression test; funnel plot asymmetry on the natural




The initial search retrieved a total of 86 references, and
after screening titles and abstracts of identified articles,
38 were excluded because they were not related to the
current study. Upon further review, 34 were excluded
because they were either laboratory studies or records
without survival data. Then we evaluated 14 potential
candidate studies in full text. It was found that the sur-
vival data of one article could not be used in this study.
Finally, 6 [19-24] studies were included in this meta-
analysis, which were published between1994 and 2014
(Figure 1). All of them were retrospective in design. In
each study, the cut-off values of CD44 appeared to be
different. The main characteristics of the included studies
were summarized in Table 1.
Meta-analysis
For studies evaluating overall survival (OS), there was no
between-study heterogeneity among those six studies for
CD44 (I2 = 0%), so the fixed-effect model was used to
calculate the pooled HR with corresponding 95% CI.
The result indicated that positive expressions of CD44
did not predict neoplasm metastasis (RR = 1.36, 95% CI:
1.00–1.84, P = 0.50), and higher expression of CD44
could not predict poorer survival in osteosarcoma with
the pooled HR of 0.55 (95% CI: 0.27–1.13, P = 0.47).
(Figures 2, 3)
Publication bias
Funnel plot and Egger’s test were used to evaluate the
publication bias of the literatures. The shape of the funnel
plot did not reveal any evidence of obvious asymmetry
(Figures not shown).
Figure 1 Flow diagram of the study selection process.
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Osteosarcoma is a life-threatening bone malignancy that
often occurs in teenagers. It is the second leading cause
of cancer-related death in pediatric age group and young
adults [25]. Current treatments for osteosarcoma include
surgical resection of both primary and pulmonary lesions,
chemotherapy, and radiotherapy. Disease-free survival
escalated from <20% prior to the introduction of effect-
ive chemotherapy to around 60% and overall survival to
60–70% [26]. At present, the ability to predict the prog-
nosis of osteosarcomas is limited. Therefore, identifying
prognostic markers of survival in osteosarcomas could be
informative for selecting proper management. Traditional
prognostic markers, such as gender, age, tumor location,
disease-free interval, tumor doubling time, representation,
and number of detectable pulmonary metastases, have
had limited success in identifying those patients that needTable 1 Characteristics of studies included in the meta-analys
Study Year Age (median) No. of patients Method CD4
Boldrini et al. [19] 2010 15.9 34 IHC ≥
Deng et al. [20] 2013 18.3 90 IHC ≥
Gvozdenovic et al. [21] 2013 NA 53 IHC
Kim et al. [22] 2002 17 50 IHC ≥
Kuryu et al. [23] 1999 19 39 IHC ≥
Ma et al. [24] 2011 16 63 IHCaggressive chemotherapy and those that do not [27]. In re-
cent years, a number of cell surface markers were found
to indicate a small group of cancer cells, referred as cancer
stem cells, which are responsible for tumor initiation,
progression, metastasis and drug resistance [28]. Many
researchers have reported that high expression of these
markers indicates bad clinical features and poor prognosis
[29,30], and CD44 was one of the most reported cancer
stem cells markers.
CD44 was previously thought to be a transmembrane
adhesion molecule, which also played a role in the me-
tabolism of its principal ligand hyaluronan. It may exist
in three distinct physical phases, as a transmembrane
cell surface receptor, an integral component of the
matrix and in a fluid phase, each with the potential for
being functionally significant. CD44 is known to be a
major hyaluronic acid receptor in vitro, although it is
not known how often CD44 is expressed or what role it
plays in normal bone tissues. CD44 proteins have been
observed in osteoclasts and osteocytes by means of immu-
nohistochemical analysis on bone tissue, but there have
been some controversial reports that CD44 proteins were
found in osteoblasts [31]. As CD44 reacts with the extra-
cellular matrix, several published reports have suggested
that CD44 expression is related to metastatic potential,
prognosis, and the biologic properties of human malig-
nancies. Investigations of CD44 over the past 20 years
have established additional functions for CD44, including
its capacity to mediate inflammatory cell function, tumor
growth, adhesion, migration and metastasis. It has also
become evident that intricate post-translational modifica-
tions of CD44 regulate the affinity of the receptor for its
ligands [32]. Whether CD44 is a prognostic marker in
osteosarcoma patients has been studied extensively, but
the conclusions are inconsistent. This meta-analysis was
carried out by critically reviewing six studies on the asso-
ciation of CD44 with prognosis in osteosarcoma.
The present meta-analysis showed that high CD44
expression did not indeed predict poor survival and
metastasis in patients with osteosarcoma. However, it
should be circumspect to make a verdict of the associationis
Expression
of CD44 (n)
OS/RFS (%) Metastasis (n)
4 cut-off Positive Negative CD44 (+) CD44 (−) CD44 (+) CD44 (−)
10% 17 17 21.5% 25.3% NA NA
25% 59 31 NA NA 38 12
NA 9 44 NA NA 4 15
50% 10 40 NA NA 4 22
10% 18 21 24% 58% 13 10
NA 62 1 40.3% 0% 12 0
Figure 2 CD44 expression and overall survival rate of osteosarcoma patients.
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several issues should be considered. First, since the
number of included studies in this meta-analysis was
only six, it might weaken the reliability of our results.
More well-designed clinical studies with large cases of
osteosarcoma should be performed in the future to val-
idate the relationship between CD44 expression level
and prognosis of osteosarcoma patients. Second, lack of
abundant CD44 expression data in global population
makes it difficult to set a standard value for the measure-
ment of CD44. Third, the methods used for the evaluation
of the levels of markers in osteosarcoma patients and the
use of standard threshold, are both likely to impact on our
results. Although immunohistochemistry was the most
commonly applied method, the cut-off value was defined
differently in inclusion studies. Therefore, we strongly sug-
gest conducting more prognostic studies for high CD44
expression in osteosarcoma.
Moreover, recently studies have demonstrated that
microRNAs might influence chemoresistance of osteo-
sarcomas with different pathways including CD44, resist-
ance to chemotherapeutic agents is still one of the major
reasons for the failure of osteosarcoma treatment, while
we did not excluded the role of CD44 in chemoresistance
of osteosarcoma. The identification of cancer-specific
miRNAs and their targets is pivotal for understanding
their role in tumorigenesis and metastasis, and may be
important for the discovery of novel therapeutic targets.Figure 3 CD44 expression and metastasis of osteosarcoma patients.CD44 which contained the corresponding binding site
of microRNAs’ 3′UTR, was regulated by some micro-
RNAs, such as miR-34a, miR-140 and miR-215 [33-35].
The results of these published studies showed that the
CD44 level inversely correlated with the microRNAs level.
So in the future research, we will discuss the role of CD44
in chemoresistance of osteosarcoma.
On the other hand, many researchers have reported
that high expression of some markers indicates bad clinical
features. Such as clinical stage, positive distant metastasis
and poor response to chemotherapy [36,37]. In this present
study, we also discussed the relationship between overex-
pression of CD44 and clinicopathological parameters in
osteosarcoma patients. Nonetheless, the result showed
that no significant difference was observed between the
expression of CD44 and patients’ age, gender, tumor size,
clinical stage, positive distant metastasis and poor response
to chemotherapy (data not shown).
Despite the inherent limitations of meta-analysis on
prognostic literature, this meta-analysis, representing a
quantified synthesis of all published studies of CD44, has
shown that the high expressed CD44 is not significantly
associated with poor survival and metastasis in patients
with osteosarcoma. For better analysis the relationship
between CD44 expression and prognostic with the
osteosarcoma, it is necessary to improve the experimental
methods and detection methods, and to clear a unified
quantitative standard. Future adequately multi-center
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great value to confirm these findings and more clinical
studies should be carried out before the application of
CD44 in prognosis of osteosarcoma.Conclusions
The findings from this present meta-analysis suggest that
CD44 expression is not associated with overall survival
rate and metastasis in osteosarcoma. CD44 may not be a
useful marker to predict prognosis of osteosarcoma.
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